Navigation Links
Gene responsible for developing prostate cancer identified

Researchers from University of North Carolina have identified a molecule Ack1, which is responsible for suppressing the activity of Tumor// suppressor protein. Tumor suppressor protein is responsible for maintaining the integrity of cell and prevents the cell from developing tumor by maintaining a control growth of cell. Ack1 is found to be a growth promoting tyrosine kinase gene family. The results of the study has been published in the Journal Cancer research.

Tests of Ack1 demonstrate a profound effect on tumor growth in experimental systems, Earp said. 'It's a remarkable effect. Tumors grew more rapidly and invaded as if they were converted to advanced prostate cancer.'

Another major finding of the study involved an experimental drug developed by the National Cancer Institute, called geldanamycin. In laboratory tests, the UNC Lineberger group found Ack1 activity could be inhibited through interference with its molecular interactions, thus offering a target for treatment. First, the group discovered that Ack1 bound to a protein called Hsp90 (heat shock protein 90), which associated with many oncogenic, or cancer-causing, signaling proteins.

'If you add geldanamycin to the prostate cancer cell, the drug knocks Hsp90 off oncogenic signaling molecules. This dramatically decreases Ack1 activity and slows tumor formation,' Earp said.

In addition, the team compared Ack1 activation in advanced prostate cancer tissue from patients with that found in benign prostatic hypertrophy, or non-cancerous prostate enlargement. The team showed the levels of the activated Ack1 to be much higher in the advanced tumors.

'We saw that Mer was expressed at reasonably high levels in prostate cancer cells. And so Dr. Nupam Mahajan, the study's first author, decided to look at whether Mer had an effect on prostate cancer growth signaling,' Earp said. In experiments, which used the university's Michael Hooker Proteomics Core Facility, the team discovered that Mer activated Ack1. This finding led to the current study. 'Because we found Ack1 is more active in advanced prostate tumors, and its inhibition blocks experimental tumor growth, we believe Ack1 should be a target for novel drug development.'


'"/>




Related medicine news :

1. The right is responsible
2. Gene responsible for depression
3. Gene responsible for immune deficiency discovered
4. Genes responsible for social behavior of us
5. Molecule responsible for muscle repair identified
6. Genes responsible for cancer in women associated with increased cancer risk in men
7. Fixational eye movement responsible for visibility
8. Metal traces in infant formula cans responsible for recall.
9. Get that wedding ring on if you want to be branded a responsible parent!
10. Greater g factor in men responsible for sex differences in general mental ability
11. Molecule responsible for age associated macular degeneration identified
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... ... September 19, 2017 , ... Public outrage over the toxins that exist ... deaf ears, leaving the water industry itself to research, develop and ultimately supply consumers ... curve in the field of natural alkaline water technologies, water filtration ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler ... in the U.S. to incorporate magnesium, a critical property for bone health and ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... Ron Norman, ... candidates today the importance of making a distinct rather than generic impression in the ... had to look through a stack of resumes knows that the first impression they ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... to the Certified Emergency Nurse (CEN®) certification according to a large-scale ... value of certification study, conducted by the Human Resources Research Organization (HumRRO) in ...
(Date:9/18/2017)... , ... September 18, 2017 , ... A September 7 ... in Belfast indicating that aspirin, one of the world’s most common and least expensive ... Los Angeles area dentist Dr. Farzad Feiz of California Dental Group and Calabasas Dental ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Sept. 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting ... Rodman & Renshaw 19 th Annual Global Investment ... (12:25 p.m. Pacific time). The conference is being held at ...
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
Breaking Medicine Technology: